Product Images Crysvita

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 9 images provide visual information about the product associated with Crysvita NDC 42747-203 by Kyowa Kirin, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Figure 1 - crysvita 01

Figure 1 - crysvita 01

Figure 2 - crysvita 02

Figure 2 - crysvita 02

This appears to be a graph or chart depicting the results of a clinical trial involving a drug called CRYSVITA. The graph shows the serum phosphorus levels of participants during a double-blinded period and an open-label period. Placebo and CRYSVITA were both used in the trial, with CRYSVITA showing an improvement in serum phosphorus levels compared to the placebo group. However, without more context or information about the trial, it's difficult to provide a full description of the results.*

Figure 3 - crysvita 03

Figure 3 - crysvita 03

PRINCIPAL DISPLAY PANEL - 10 mg/mL Vial Carton - crysvita 04

PRINCIPAL DISPLAY PANEL - 10 mg/mL Vial Carton - crysvita 04

This appears to be a label of a medication called CRYSVITA, produced by Kyowa Kirn Inc. It is a 1.5 mL 1" Disposable Unised Perinjectonsite, intended for subcutaneous use only. The medication contains 10 mg of Burosumab-Twza, a potency drug, and must be refrigerated when stored. The label also contains an NDC number, which could be used for identification and tracking purposes.*

PRINCIPAL DISPLAY PANEL - 30 mg/mL Vial Carton - crysvita 05

PRINCIPAL DISPLAY PANEL - 30 mg/mL Vial Carton - crysvita 05

This is a medication label. The name of the medication is CRYSVITA made by AN and manufactured in Princeton, NJ. The medication is administered via subcutaneous injection and must be refrigerated. The Polysorbate 80 and Burosumab-twza are some of the ingredients. The single-dose vial should be discarded once 1.5 mL volume has been used, and the unused portion should be discarded as well. NDC ID is 42747-304-01.*

PRINCIPAL DISPLAY PANEL - 20 mg/mL Vial Carton - crysvita 06

PRINCIPAL DISPLAY PANEL - 20 mg/mL Vial Carton - crysvita 06

PRINCIPAL DISPLAY PANEL - 10 mg/mL Vial - crysvita 07

PRINCIPAL DISPLAY PANEL - 10 mg/mL Vial - crysvita 07

C RYSVITA® is a medication available in the form of a single-dose vial injection containing 10 mg/mL of burosumab-twza. It is manufactured by Kyowa Kirin, Inc. and its NDC number is 42747-102-01. The medication is used to treat a rare genetic disorder called X-linked hypophosphatemia (XLH).*

PRINCIPAL DISPLAY PANEL - 20 mg/mL Vial - crysvita 08

PRINCIPAL DISPLAY PANEL - 20 mg/mL Vial - crysvita 08

This appears to be a description of a pharmaceutical product. The product name is CRYSTALTA, with the National Drug Code 42747-203-01. It comes in a single-dose vial of 1 mL and is given by injection. The manufacturer is Kyowa Kirin, Inc. The product has a lot number and an expiry date, but these are illegible in the provided text.*

PRINCIPAL DISPLAY PANEL - 30 mg/mL Vial - crysvita 09

PRINCIPAL DISPLAY PANEL - 30 mg/mL Vial - crysvita 09

This is a description of a medication called "burosumab-twza". It comes in a 1 mL vial as an injection with a concentration of 0 mg/mL produced by Kyowa Kirin, Inc. There is a U.S. license number and an expiration date indicated. The rest of the text is not clear and appears to be incomplete or illegible.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.